Table of Contents
CHESTERFIELD, United Kingdom — Mallinckrodt plc is building out a new campus in Bedminster, N.J., to house its rapidly growing specialty brands organizations.
The drug maker said it plans to invest more than $80 million in New Jersey and expects about 400 employees to occupy the new space in the first quarter of 2017. The new specialty brands campus is located at the Somerset Financial Center, 1405-1425 Route 206, in Bedminster.
Mallinckrodt also has commenced the next phase of construction at its downtown St. Louis manufacturing facility. The effort is part of more than $140 million in capital projects and related expenses invested in offices and plant locations for the company’s legacy businesses and its key administrative functions.
“As we began to transform Mallinckrodt into a specialty pharmaceutical organization, we acquired a base of established operations on the East Coast,” according to Mark Trudeau, president and chief executive officer of Mallinckrodt. “With this base, and recognizing the important concentration of specialty pharmaceutical talent and intellectual capital in the area, we believe consolidating our specialty brands organizations in New Jersey provides compelling value. We believe the state will be a great business destination for the company.”
“I’m pleased to welcome Mallinckrodt to Bedminster and look forward to future collaboration with the company as they build their specialty brands business here in the Garden State,” New Jersey Lt. Governor Kim Guadagno said in a statement. “New Jersey provides a favorable environment for the growth of pharmaceutical companies, given the wide range of business incentives we offer and our highly skilled and educated workforce.”
Mallinckrodt said that in late 2015, the company found itself with commercial and development operations spread across over a dozen U.S. sites after multiple acquisitions during the previous 18 months. The Bedminster campus will consolidate operations for the specialty brands groups, co-locating more than 400 commercial and science employees focused on marketed and development products in the company’s autoimmune and rare diseases and hospital businesses.
“Bedminster is an excellent setting for Mallinckrodt, allowing us to design a work space that will meet the needs of our dynamic, fast-growing business while providing an exceptional working environment to support collaboration among our employees,” Trudeau added.
Meanwhile, Mallinckrodt continues to reinvest in St. Louis, where the company’s roots date back almost 150 years. Recent investment includes the commitment of more than $8 million for expansion of its downtown St. Louis manufacturing facility plus a $12 million site addition opened in mid-2015 to increase manufacturing efficiency.
“For decades, Mallinckrodt has proudly maintained a significant presence in St. Louis, where many of us continue to live and work,” Trudeau commented, “and we’re excited to reinforce that presence in this region with continued reinvestment.”
